|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-1-11
|
|
pubmed:abstractText |
The most successful clinical studies of immunotherapy in patients with non-Hodgkin's lymphoma (NHL) use the antibody rituximab (RTX) targeting CD20(+) B-cell tumors. Rituximab radiolabeled with ?(-) emitters could potentiate the therapeutic efficacy of the antibody by virtue of the particle radiation. Here, we report on a direct radiolabeling approach of rituximab with the (99m)Tc- and (188)Re-tricarbonyl core (IsoLink technology).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1872-9614
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
38
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
19-28
|
|
pubmed:meshHeading |
pubmed-meshheading:21220126-Animals,
pubmed-meshheading:21220126-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:21220126-Antigens, CD20,
pubmed-meshheading:21220126-Autoradiography,
pubmed-meshheading:21220126-Cell Line, Tumor,
pubmed-meshheading:21220126-Cysteine,
pubmed-meshheading:21220126-Drug Stability,
pubmed-meshheading:21220126-Female,
pubmed-meshheading:21220126-Histidine,
pubmed-meshheading:21220126-Humans,
pubmed-meshheading:21220126-Isotope Labeling,
pubmed-meshheading:21220126-Lymphoma, Non-Hodgkin,
pubmed-meshheading:21220126-Mice,
pubmed-meshheading:21220126-Organotechnetium Compounds,
pubmed-meshheading:21220126-Radioisotopes,
pubmed-meshheading:21220126-Rhenium
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Radiolabeling of rituximab with (188)Re and (99m)Tc using the tricarbonyl technology.
|
|
pubmed:affiliation |
Instituto de Pesquisas Energéticas e Nucleares, Av Professor Lineu Prestes 2242, 05508-000 São Paulo, Brazil.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
